EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease

Anna Laura Knoblauch, B-I Blaß, C Steiert, N Neidert, A Puzik, E Neumann-Haefelin, A Ganner, F Kotsis, T Schäfer, H P H Neumann, S Elsheikh, J Beck und 1 weitere

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04676-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Anna Laura Knoblauch und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Breisacher Str. 64, 79106, Freiburg…. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Hemangioblastoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Freiburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome. One of the most common tumors are central nervous system (CNS) hemangioblastomas. Recommendations on the initiation and continuation of the screening and surveillance program for CNS tumors in pediatric VHL patients are based on small case series and thus low evidence level. To derive more robust screening recommendations, we report on the largest monocentric pediatric cohort of VHL patients.

Methods

We performed a retrospective analysis on a pediatric cohort of 99 VHL patients consulted at our VHL center from 1992 to 2023. Clinical, surgical, genetic, and imaging data were collected and statistically analyzed.

Results

42 patients (50% male) developed CNS hemangioblastomas, of whom 18 patients (56% male) underwent hemangioblastoma surgery (mean age at first surgery: 14.9 ± 1.9 years; range 10.2–17). The first asymptomatic patient was operated on at the age of 13.2 years due to tumor progress. Truncating VHL mutation carriers had a significantly higher manifestation rate (HR = 3.7, 95% CI: 1.9–7.4, p < 0.0001) and surgery rate (HR = 3.3, 95% CI: 1.2–8.9, p = 0.02) compared with missense mutation carriers.

Conclusion

We recommend starting MRI imaging at the age of 12 years with examination intervals every (1-) 2 years depending on CNS involvement. Special attention should be paid to patients with truncating variants. Affected families should be educated regularly on potential tumor-associated symptoms to enable timely MRI imaging and eventually intervention, as CNS hemangioblastoma may develop before screening begins. German clinical trials Register registration number DRKS00029553, date of registration 08/16/2022, retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Hippel-Lindau DiseaseHemangioblastomaHumansMaleFemaleAdolescentChildRetrospective StudiesCerebellar NeoplasmsCentral Nervous System NeoplasmsFollow-Up StudiesVon Hippel-Lindau Tumor Suppressor Protein

Stichwörter der Autor:innen

AdolescenceHemangioblastomaPediatric neurosurgerySurveillanceVon Hippel-Lindau

Substanzen

Von Hippel-Lindau Tumor Suppressor Protein

Autor:innen und Institutionen

  • Department of Neurosurgery, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany. annalaura.knoblauch@web.de.
  • Department of Neurosurgery, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany.
  • Berta-Ottenstein-Programme for Clinician Scientists, Medical Center - University of Freiburg, Freiburg, Germany.
  • Department of Pediatric Hematology and Oncology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Renal Division, Department of Medicine, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Department of Neuroradiology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.

Förderung

  • Universitätsklinikum Freiburg

Zitieren

APA

Knoblauch, A. L., Blaß, B. I., Steiert, C., Neidert, N., Puzik, A., Neumann-Haefelin, E., Ganner, A., Kotsis, F., Schäfer, T., Neumann, H. P. H., Elsheikh, S., Beck, J., & Klingler, J. H. (2024). Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04676-5

Vancouver

Knoblauch AL, Blaß BI, Steiert C, Neidert N, Puzik A, Neumann-Haefelin E, et al. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04676-5

BibTeX
@article{Knoblauch2024,
  author = {Knoblauch, Anna Laura and Blaß, B-I and Steiert, C and Neidert, N and Puzik, A and Neumann-Haefelin, E and Ganner, A and Kotsis, F and Schäfer, T and Neumann, H P H and Elsheikh, S and Beck, J and Klingler, J-H},
  title = {Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04676-5}
}
Kostenlos starten →